Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Mobile Distress Screening in Orthopedic Oncology - a Smartphone-based Cancer-specific Assessment in Patients With Sarcoma.

Created on 01 Sep 2026

Authors

Florian Lenze, Lilian Engemann, Sebastian Breden, Sara Consalvo, Carolin Knebel, Andreas Dinkel, Dietmar Dammerer, Rüdiger VON Eisenhart-Rothe, Ulrich Lenze

Published in

Anticancer research. Volume 46. Issue 9. Pages 5003-5011.

Abstract

A substantial proportion of patients with cancer experience clinically relevant psycho-oncological distress. In addition to clinic-based screening, mobile approaches are receiving increasing attention for standardized assessment. However, evidence in patients with musculoskeletal sarcoma remains limited.
Forty-five patients with sarcoma underwent smartphone-based distress screening using a cancer-specific questionnaire (QSC-R10) at two time points (T1 and T2). At T1, patients also completed the System Usability Scale (SUS) and additional acceptability items.
Mean QSC-R10 scores decreased significantly from T1 to T2 (p=0.034). Patients with recurrent disease showed significantly higher distress at follow-up (p=0.012). Usability was high (SUS: 83.78±12.68), and overall acceptance was high.
Smartphone-based distress screening is feasible and well accepted in patients with musculoskeletal sarcoma and may improve the identification of psycho-oncological needs through repeated, real-world assessments.

PMID:
42674702
Bibliographic data and abstract were imported from PubMed on 01 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement